A Multicenter, Open-Label, Randomized, Phase 2 Study to Evaluate the Efficacy and Safety of NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naive, KRAS-Mutant, Metastatic Colorectal Cancer (mCRC)
Phase of Trial: Phase II
Latest Information Update: 10 Aug 2017
At a glance
- Drugs Etirinotecan pegol (Primary) ; Irinotecan
- Indications Colorectal cancer
- Focus Therapeutic Use
- Sponsors Nektar Therapeutics
- 09 Aug 2017 This trial has been discontinued in Belgium, as per European Clinical Trials Database record.
- 24 Feb 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 05 Aug 2014 Planned primary completion date changed from 1 Jun 2014 to 1 Aug 2014 as reported by ClinicalTrials.gov.